FN1 and cancer: Mitra et al. have shown that siRNA or therapeutic antibody blockade of the cancer cell fibronectin binding partner α5β1-integrin inhibits c-Met/FAK/Src signaling and is therefore effective in both prevention and intervention settings [92].